Erin Haleem, Ms
About Erin Haleem, Ms
Erin Haleem is a Senior Scientist in Biologics Development - Upstream PD at Bristol Myers Squibb, with extensive experience in antibody, gene therapy, and vaccine development.
Senior Scientist at Bristol Myers Squibb
Erin Haleem is currently a Senior Scientist in Biologics Development, focusing on Upstream Process Development (PD) at Bristol Myers Squibb. She contributes to the advancement of biologics through data-centric support for process development and modeling, with a keen interest in the implementation of new technologies.
Career at Bristol Myers Squibb
Erin Haleem has held various roles at Bristol Myers Squibb. She began as Scientist I in Biologics, Upstream PD from 2019 to 2020, then progressed to Scientist II in Biologics Development - Upstream PD for 5 months in 2020-2021, before assuming her current role as Senior Scientist in Biologics Development - Upstream PD.
Previous Roles in Biologics Development
Before joining Bristol Myers Squibb, Erin Haleem worked at Celgene as Scientist I in Upstream PD, Biologics Development & Manufacturing for 6 months in 2019. She also held positions at REGENXBIO Inc. as Senior Associate Scientist and Associate Scientist in Upstream PD from 2017 to 2019, and at NOVAVAX INC as Bioprocess Engineer - MS&T and Manufacturing Associate II from 2014 to 2016.
Early Career and Education
Erin Haleem started her career with roles at Science and Technology Corporation (STC) and the United States Department of Defense. She holds an M.S. in Biotechnology from The Johns Hopkins University and a B.S. in Biological Systems Engineering: Bioprocess Engineering from Virginia Polytechnic Institute and State University. During her undergraduate studies, she conducted research in the Renewable Materials Lab at Virginia Tech.
Expertise in Biologics Development
Erin Haleem has extensive experience in antibody, gene therapy, and vaccine development. She is adept in utilizing transient and stable cell lines across mammalian, insect, and bacterial systems. Additionally, she possesses a strong working knowledge of offline process analyzers and both bench-top and single-use pilot scale bioreactors.